U.S. Drug Repurposing Market to Reach USD 17.98 Billion and Europe USD 14.51 Billion by 2035 as Pharma Expands Established Drug Portfolios Across New Therapeutic Opportunities

Austin, United States, Sept. 07, 2026 (GLOBE NEWSWIRE) -- Drug Repurposing Market Size & Growth Analysis:

According to SNS Insider, The Drug Repurposing Market size was valued at USD 34.79 Billion in 2025 and is expected to reach USD 50.91 Billion by 2035, growing at a CAGR of 3.93% from 2026 to 2035. The demand is growing due to the increasing need for efficient and affordable methods of drug development, which can be achieved by re-purposing already developed drugs, thereby saving money and time spent on research and development processes. Interest in rare diseases and unmet medical needs as well as the emergence of new infections will fuel further adoption, being encouraged by advances in the field of artificial intelligence, drug screening, and databases, which enhance drug repurposing discovery process.

Artificial intelligence and machine learning are used for modernizing the process of drug repurposing through analysis of biological, clinical, and molecular databases, while increasing number of genomic, proteomic, and real-world evidence improves discovery of novel drug-disease targets.


Download the Drug Repurposing Market Sample Report: https://www.snsinsider.com/sample-request/10952

Drug Repurposing Market Key Highlights

  • Market size, 2025: USD 34.79 Billion
  • Market forecast, 2035: USD 50.91 Billion
  • CAGR: 3.93% from 2026 to 2035
  • Largest region: North America, approximately 39% share in 2025
  • Fastest-growing region: Asia Pacific, approximately 5.02% CAGR
  • Largest drug type: Small Molecules, approximately 67% share in 2025
  • Fastest-growing drug type: Biologics, approximately 4.39% CAGR
  • Largest therapeutic area: Oncology, approximately 28% share in 2025
  • Fastest-growing therapeutic area: Neurology and CNS Disorders, approximately 5.58% CAGR
  • Largest route of administration: Oral, approximately 55% share in 2025
  • Fastest-growing route of administration: Intravenous, approximately 4.64% CAGR
  • Largest end use: Pharmaceutical and Biopharmaceutical Companies, approximately 58% share in 2025
  • Fastest-growing end use: Contract Research Organizations (CROs), approximately 4.71% CAGR

Market Relevance

Repurposing drugs is becoming more popular for the pharmaceutical industry as a method of research because, by repurposing drugs, companies can use already existing knowledge about the medicine’s safety, pharmacological properties, manufacturing process, and clinical trial data instead of conducting all research work anew. This way, drug repurposing is faster than drug discovery; hence, its popularity in treating rare diseases and novel infections.

Drug Repurposing Market Overview

The market consists of small molecules and biologics that have been reformulated for new indications using oral and intravenous administration routes in order to be developed by pharmaceutical and biopharmaceutical firms and contract research organizations. Small molecules are still popular owing to their safety profiles, established pharmacology, and already existing manufacturing processes, whereas biologics reformulation is becoming more widespread on account of data generated from clinical trials and safety assessments making development process faster. Oncology and neurology are among major areas of applications for these products, which benefit from artificial intelligence and computing technologies.

Strategic Market Outlook

Opportunities in this space include the fast integration of AI, machine learning, natural language processing, and biomedical knowledge graphs, which have the ability to process massive amounts of genomic, clinical, and molecular data to find relationships between already existing drugs and new disease targets. Increased funding for computational approaches and increased cooperation between pharmaceutical companies and AI technologies companies continue to make this opportunity grow.

Insufficient intellectual property rights are one of the main barriers to development in this field. A large number of drugs that could be repurposed has expired or pending patents, and this fact makes it hard for the drug developers to ensure necessary exclusivity, which reduces the motivation to finance their clinical and commercial development.

Drug Repurposing Market Regional Analysis

The region of North America had around 39% share of the world market in 2025, thereby becoming the dominant one, owing to its developed pharmaceutical research and development capacities, advanced healthcare structure, and ecosystem for drug discovery driven by artificial intelligence. The USA constituted around 88.5% share of revenue from North America, which was facilitated by the advanced pharmaceutical industry, clinical research capacity, and significant investment in drug discovery in the country.

The U.S. Drug Repurposing Market was valued at USD 12.35 Billion in 2025 and is expected to reach USD 17.98 Billion by 2035, growing at a CAGR of 3.88% from 2026 to 2035. In May 2026, the FDA expanded its focus on drug repurposing for chronic and rare diseases, strengthening the regulatory environment for repurposed therapies.

The Europe Drug Repurposing Market commanded roughly 29% of the total share in the worldwide market and was valued at USD 10.09 Billion in 2025 and is forecasted to rise to USD 14.51 Billion by 2035, registering a growth rate of 3.70% from 2026 to 2035. The growth is propelled due to advanced infrastructure for pharmaceutical research and EU-sponsored initiatives like REPO4EU and REMEDi4ALL, which improve collaboration and AI-based drug discovery. Germany held roughly 31.0% share in terms of revenue generated in Europe in 2025, owing to its robust pharmaceutical and biotechnology industry and extensive research activity.

The Asia-Pacific region commands the highest growth rate of around 5.02% between 2026 to 2035 owing to the development in pharmaceutical and biotechnology industry, increasing healthcare expenditure, and increasing research capacity. China held approximately 39.0% share in regional revenue in 2025, owing to increasing research and development capacity in pharmaceuticals and rising applications of computational biology and artificial intelligence.

Middle East & Africa: The UAE accounted for approximately 15.0% of regional revenue in 2025, supported by improving healthcare infrastructure and rising pharmaceutical investment.

Latin America: Brazil led regional revenue at approximately 38.0% in 2025, supported by growing healthcare investment and unmet medical needs.

Buy the Drug Repurposing Market Report with Competitive Analysis and 2035 Forecast: https://www.snsinsider.com/checkout/10952

Drug Repurposing Market Segment Analysis

By Drug Type: Small Molecules held a 67% market share in 2025 due to their safety, clinical data, and existing manufacturing facilities. Biologics is the fastest-growing category, with a CAGR of 4.39%, due to the rising popularity of repositioning antibodies and recombinant proteins.

By Therapeutic Area: The market share in Oncology was estimated to be about 28% in 2025 due to considerable research work and drug availability based on pharmacodynamics. The Neurology and CNS Disorders is the most rapidly growing segment at the growth rate of 5.58%, due to treatment deficiencies and disease complexity.

By Route of Administration: The oral delivery format captured approximately 55% of market share in 2025, aided by convenience and compliance. The fastest growing mode of delivery is the intravenous segment with a compound annual growth rate of 4.64%, driven by increased repurposing of biologics requiring systemic, controlled administration.

By End Use: The Market Share held by Pharmaceutical and Biopharmaceutical Companies was about 58% in 2025 due to their drug libraries, clinical research skills, and regulatory knowledge. The fastest growing segment is Contract Research Organizations, which had an annual growth rate of about 4.71% CAGR, driven by rising outsourcing of discovery, trials, and regulatory activities.

Drug Repurposing Market Key Trends

  • Rising demand for faster, cost-effective drug development driving adoption of repurposing strategies
  • Increasing prevalence of rare, chronic, and emerging diseases encouraging alternative therapeutic applications for established drugs
  • Growing adoption of AI and machine learning accelerating repurposing by analyzing biological and clinical datasets
  • Increasing availability of genomic and real-world evidence improving identification of drug-disease associations
  • Rising pharmaceutical research costs encouraging companies to leverage existing safety data for new indications

Competitive Landscape

The Drug Repurposing Market includes established pharmaceutical companies and AI-driven repurposing platforms, with competition centred on computational drug discovery and expanding rare-disease indications.

In 2026, Every Cure continued expanding its AI-driven drug repurposing platform, using large-scale biomedical data to identify existing medicines for diseases with significant unmet need. REMEDi4ALL continued advancing international repurposing programs focused on rare diseases, cancers, and infectious diseases. Recursion Pharmaceuticals continued advancing AI-enabled discovery and repurposing by integrating large-scale biological datasets and automated experimentation. In 2025, Every Cure developed its AI-enabled end-to-end repurposing platform to systematically identify and advance existing medicines for new therapeutic indications.

Major key players include

  • AbbVie Inc.
  • Amgen Inc.
  • Boehringer Ingelheim International GmbH
  • Eli Lilly and Company
  • GSK plc
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.
  • AstraZeneca plc
  • Johnson & Johnson
  • Takeda Pharmaceutical Company Limited
  • Bristol Myers Squibb Company
  • Roche Holding AG
  • Biogen Inc.
  • Recursion Pharmaceuticals, Inc.
  • Evotec SE
  • Melior Discovery, Inc.
  • SOM Biotech S.L.
  • Every Cure
  • NovaLead Pharma Pvt. Ltd

Explore the Complete Drug Repurposing Market Report: https://www.snsinsider.com/reports/drug-repurposing-market-10952 

CONTACT: About Us:
SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.

Contact Us:
Rohan Jadhav - Principal Consultant
Phone: +1-315-961-9094 (US)
Email: info@snsinsider.com